文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

全脑放疗后认知下降:治疗前脑白质病变与高龄患者的预测因素

Patients with pretreatment leukoencephalopathy and older patients have more cognitive decline after whole brain radiotherapy.
PubMed 文献 · Radiat Oncol · 2020-11-25

该研究为一项2期临床试验的二次分析,纳入46例接受立体定向放射外科和全脑放疗的脑转移患者,采用MoCA评估认知功能,Fazekas量表评估基线白质高信号。结果显示年龄、基线WMH体积和Fazekas评分≥3/6均预测MoCA评分下降,多因素分析中仅年龄为显著预测因子;3例治疗前Fazekas评分6/6的患者均出现严重认知不良结局。

要点

  • 年龄、基线WMH体积和Fazekas评分≥3/6预测全脑放疗后MoCA评分下降。
  • 多因素分析中年龄是唯一显著预测因子。
  • 治疗前Fazekas评分6/6的3例患者均出现严重认知不良结局。

核心结论

  • 高龄和基线白质高信号负荷较高的患者在全脑放疗后认知下降更明显。
  • 研究规模小且为假设生成性,但建议治疗前影像存在脑白质病变时慎用全脑放疗。

研究设计与样本

  • 一项2期临床试验(NCT01046123)的二次分析,纳入接受立体定向放射外科治疗1-10个脑转移灶并接受全脑放疗的患者。
  • 共46例患者治疗后生存≥3个月,基线及全脑放疗后每3个月进行MoCA评估。
  • 基线T2-FLAIR MRI由两名神经放射科医生独立用Fazekas视觉评定量表评估白质高信号,并手动分割进行体积分析。
  • 采用单因素和多因素逻辑回归检验基线变量与MoCA评分下降的关联。

主要发现

  • 年龄(OR 1.12,95%CI 1.04-1.21,p<0.01)、基线WMH体积(OR 1.20,95%CI 1.06-1.52,p=0.02)和基线Fazekas评分≥3/6(OR 6.4,95%CI 1.7-24.7,p<0.01)预测MoCA评分下降。
  • 多因素分析中,年龄是MoCA评分下降的唯一显著预测因子。
  • 3例治疗前Fazekas评分6/6的患者均出现认知障碍导致的不良结局:1例需全职家庭护理支持,2例被收治入院。

关键数值与推荐

  • 基线Fazekas评分≥3/6定义为白质高信号负担较高,其预测MoCA下降的OR为6.4(95%CI 1.7-24.7,p<0.01)。
  • 基线WMH体积每增加一个单位,MoCA下降的OR为1.20(95%CI 1.06-1.52,p=0.02)。
  • 年龄每增加一岁,MoCA下降的OR为1.12(95%CI 1.04-1.21,p<0.01)。

临床怎么用

  • 对高龄脑转移患者进行全脑放疗决策时应关注认知下降风险。
  • 治疗前影像存在脑白质病变(尤其Fazekas评分高)时,应谨慎处方全脑放疗。

局限性

  • 研究样本量小(46例),为假设生成性二次分析。
  • 仅3例治疗前Fazekas评分6/6,相关不良结局的证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate predictors of cognitive decline after whole brain radiotherapy (WBRT) for brain metastases. METHODS: A secondary analysis of a phase 2 clinical trial was conducted in patients who received stereotactic radiosurgery for 1-10 brain metastases and WBRT (NCT01046123). The Montreal Cognitive Assessment (MoCA) was performed at baseline and every 3 months after WBRT. Baseline T2-weighted fluid attenuation inversion recovery magnetic resonance imaging was independently assessed by two neuroradiologists for the presence of white matter hyperintensities (WMH) using the Fazekas visual rating scale. WMH were also manually segmented for volumetric analysis. Univariable and multivariable logistic regression were used to test the association between baseline variables and MoCA score decline. RESULTS: Forty-six patients survived ≥ 3 months after treatment. Age (OR 1.12 (1.04-1.21), p < 0.01), baseline WMH volume (OR 1.20, 95% CI 1.06-1.52, p = 0.02) and baseline Fazekas score ≥ 3/6 (OR 6.4, 95% CI 1.7-24.7, p < 0.01) were predictive of MoCA score decline. In multivariable analysis, age was the only significant predictor of MoCA decline. However, all three patients with pre-treatment leukoencephalopathy (Fazekas score = 6/6) had notable adverse outcomes due to cognitive impairment: one required full-time home nursing support and two were institutionalized. CONCLUSION: A greater decline in cognition after WBRT was observed in older patients and patients with a higher baseline WMH burden. Although this study is small and hypothesis-generating, we propose that radiation oncologists should exercise caution in prescribing WBRT if leukoencephalopathy is present on pre-treatment imaging. TRIAL REGISTRATION: clinicaltrials.gov identifier NCT01046123. First posted January 11, 2010. https://clinicaltrials.gov/ct2/show/NCT01046123.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chan M, Ferguson D, Ni Mhurchu E, et al. Patients with pretreatment leukoencephalopathy and older patients have more cognitive decline after whole brain radiotherapy. Radiat Oncol. 2020. PMID: 33239056. doi:10.1186/s13014-020-01717-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。